Migraine

Your daily dose of clinical news you may have missed.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

The role of the trigeminal nerve and its connection to the brainstem has led to a greater understanding of where migraine pain originates. Expert explains, here.

The oral calcitonin gene-related peptide receptor antagonist is now indicated for prevention in both episodic and chronic migraine.

To be marketed as Rizafilm, the product is a disintegrating film formulation of the 5-HT-1 receptor antagonist and proven bioequivalent to Merck's Maxalt-MLT.

Zavegepant, the first FDA-approved intranasal CGRP receptor antagonist, could be available in pharmacies by July 2023.

The prescription remote electrical neuromodulation device is now cleared for both acute and preventive treatment of migraine in those aged ≥12 years, according to Theranica.

Pain relief from the intranasally-delivered calcitonin gene-related peptide antagonist began as soon as 15 minutes post-dose and for some patients lasted up to 48 hours.

Your daily dose of clinical news you may have missed.

Study participants with medication overuse headache reported quality of life improvements as early as study week 4 that were sustained at week 24.

Among women with prepregnancy migraine diagnosis, rates of gestational hypertension and preeclampsia were 28% and 40% higher, respectively, vs women without migraine.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.

If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.

Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.

The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.

Gottschalk says CGRP inhibitors have made "...a life-changing transformation in how we think about and the kind of expectations we set for migraine treatment."

Christopher Gottschalk, MD, a leader in migraine research and clinical care, talks about what drew him to headache medicine early on and what it used to be like.

Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.

Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.